Rituximab: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Meg Taylor No edit summary |
||
| Line 3: | Line 3: | ||
==References== | ==References== | ||
{{reflist}} | |||
==External links== | ==External links== | ||
{{CZMed}} | {{CZMed}} | ||
Latest revision as of 01:39, 7 October 2013
In medicine, rituximab is a medication that is "a genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma."[1]
References
- ↑ Anonymous (2024), Rituximab (English). Medical Subject Headings. U.S. National Library of Medicine.
External links
The most up-to-date information about Rituximab and other drugs can be found at the following sites.
- Rituximab - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Rituximab - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Rituximab - Detailed information from DrugBank.